Aclaris Therapeutics, Inc. (NASDAQ:ACRS) – Equities research analysts at William Blair boosted their Q3 2017 EPS estimates for shares of Aclaris Therapeutics in a research report issued to clients and investors on Tuesday. William Blair analyst T. Lugo now expects that the biotechnology company will post earnings of ($0.89) per share for the quarter, up from their prior estimate of ($0.97). William Blair also issued estimates for Aclaris Therapeutics’ FY2017 earnings at ($3.16) EPS, FY2018 earnings at ($3.11) EPS and FY2019 earnings at $0.10 EPS.
Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12.
TRADEMARK VIOLATION NOTICE: This story was first posted by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright law. The legal version of this story can be accessed at https://www.com-unik.info/2017/08/12/q3-2017-earnings-forecast-for-aclaris-therapeutics-inc-issued-by-william-blair-acrs.html.
ACRS has been the topic of several other reports. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, May 12th. ValuEngine downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Jefferies Group LLC set a $36.00 price objective on shares of Aclaris Therapeutics and gave the company a “buy” rating in a report on Thursday, April 20th. Cantor Fitzgerald initiated coverage on shares of Aclaris Therapeutics in a report on Friday, June 16th. They issued an “overweight” rating and a $50.00 price objective on the stock. Finally, BidaskClub downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company. Aclaris Therapeutics presently has an average rating of “Hold” and a consensus target price of $39.00.
Shares of Aclaris Therapeutics (NASDAQ:ACRS) opened at 25.08 on Friday. The firm’s market capitalization is $670.54 million. Aclaris Therapeutics has a 52 week low of $19.30 and a 52 week high of $33.25. The company’s 50 day moving average price is $27.77 and its 200-day moving average price is $27.95.
Several hedge funds have recently added to or reduced their stakes in ACRS. State Street Corp increased its stake in Aclaris Therapeutics by 29.2% in the fourth quarter. State Street Corp now owns 170,630 shares of the biotechnology company’s stock valued at $4,631,000 after buying an additional 38,570 shares during the period. Columbus Circle Investors boosted its position in Aclaris Therapeutics by 12.9% in the first quarter. Columbus Circle Investors now owns 180,320 shares of the biotechnology company’s stock valued at $5,377,000 after buying an additional 20,642 shares in the last quarter. Rice Hall James & Associates LLC boosted its position in Aclaris Therapeutics by 0.3% in the first quarter. Rice Hall James & Associates LLC now owns 34,827 shares of the biotechnology company’s stock valued at $1,039,000 after buying an additional 93 shares in the last quarter. EcoR1 Capital LLC boosted its position in Aclaris Therapeutics by 62.6% in the first quarter. EcoR1 Capital LLC now owns 673,100 shares of the biotechnology company’s stock valued at $20,072,000 after buying an additional 259,100 shares in the last quarter. Finally, Norges Bank purchased a new position in Aclaris Therapeutics during the fourth quarter valued at about $900,000. 88.64% of the stock is currently owned by institutional investors and hedge funds.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
What are top analysts saying about Aclaris Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aclaris Therapeutics Inc. and related companies.